Scientists review the implications of extracellular vesicle (EV) release from β cells for type 1 diabetes (T1D) pathogenesis, how EVs and their cargo might be leveraged as biomarkers of this process, and how EVs might be engineered as a therapeutic candidate to counter T1D outcomes.
[Molecular Metabolism]